Arbeitsgruppe Neuroendokrine Tumoren/Karzinoide - Studien

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-NET-0217/ass: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first line chemotherapy (AveNEC study)
  --- in Rekrutierung ---

AIO-assoziierte Studie für weitere Zentren offen www.clinicaltrialsregister.eu zur Studie

AIO-NET-0117/ass: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNet study)
  --- in Vorbereitung; Initiierung der ersten Zentren im April 2018 geplant ---

AIO-assoziierte Studie   www.clinicaltrials.gov zur Studie  

AIO-NET-0417/ass: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) (COMPETE Study)
  --- in Rekrutierung ---
LETZTE AKTUALISIERUNG DIESER SEITE AM: 16.04.2019